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ABSTRACT  
Enteroviruses (EVs) are among the most frequent infectious agents in humans worldwide 
and represent the leading cause of upper respiratory tract infections. No drugs for the 
treatment of EV infections are currently available. Recent studies have also linked 
enterovirus infection with pulmonary exacerbations, especially in cystic fibrosis (CF) 
patients, and the importance of this link is probably underestimated. The aim of this work 
was to develop a new class of multi-target agents active both as broad-spectrum antivirals 
and as correctors of the F508del-CFTR folding defect responsible for >90% of CF cases. We 
report herein the discovery of the first small-molecules able to simultaneously act as 
correctors of the F508del-CFTR folding defect and as broad-spectrum antivirals against a 
panel of enteroviruses representative of all major species. 
 
INTRODUCTION 
Enteroviruses (EVs) are positive-sense single stranded RNA viruses, classified into 12 
species, including four human enterovirus species (EV-A to EV-D), three species of human 
rhinoviruses (RV-A to RV-C) and five enterovirus species that only infect animals.1 EVs are 
responsible for a great variety of clinical manifestations, especially in young children, which 
may result in life-threatening neurological complications (e.g. encephalitis, meningitis and 
poliomyelitis-like paralysis).2-4 Furthermore, RV infections are now considered one of the 
major causes of acute exacerbations in chronic pulmonary diseases like asthma, chronic 
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obstructive pulmonary disorder (COPD) and cystic fibrosis (CF) in children and adults.5 
Physicians pay particular attention to patients that already suffer from respiratory diseases, 
such as CF or asthma, as they could be particularly affected by an additional enterovirus 
infection.6 An increasing number of studies also suggest that respiratory viruses, in particular 
enterovirus and rhinovirus, contribute significantly to CF pulmonary exacerbations, 
hospitalization, decreased lung function and predisposition to bacterial colonization.7 The 
mechanistic link between viral infections and deterioration of CF lung function is not fully 
understood and their impact is probably underestimated, especially in young children.8 
Despite their high clinical and socioeconomic impact, to date there is no approved antiviral 
therapy for the prophylaxis and/or the treatment of enterovirus infections, and the 
management of patients is currently limited to symptomatic treatment and supportive care. 
Therefore, there is an unmet need for broad-spectrum antiviral drugs as a rapid defense 
strategy against enterovirus infections and virus-related exacerbations.  
Nowadays, host factors are considered as very attractive targets for the development of 
antiviral drugs because they are unlikely to mutate and develop resistance in response to 
therapy.9 Moreover, since viruses belonging to the same genus or family usually share the 
same cellular pathways for replication, targeting a host factor may allow the development of 
effective broad-spectrum antiviral compounds.10 Although some toxicity risks may be 
expected from inhibiting a host factor, it should be kept in mind that most drugs currently 
used in therapy target host proteins with excellent therapeutic outcomes and acceptable safety 
profiles. In particular, it has been well documented that the host lipid kinase 
phosphatidylinositol 4-kinase IIIβ (PI4KIIIβ) is critical for RNA replication of several 
enteroviruses.11-14 PI4KIIIβ belongs to the phosphatidylinositol 4-kinases (PI4Ks) that 
synthesize phosphatidylinositol 4-phosphate (PI4P) from phosphatidylinositol (PI). PI4P is 
involved in signaling and cellular trafficking mainly at the Golgi and trans-Golgi network 
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(TGN), it contributes to defining the characteristics of plasma membranes and it activates a 
variety of ion channels, including CFTR.15-18 Four PI4K isoforms have been identified in 
mammals, classified as type II (PI4KIIα and PI4KIIβ) or type III (PI4KIIIα and PI4KIIIβ) 
based on their primary sequences and catalytic properties.19 Type III PI4Ks are hijacked by 
several ss(+)RNA viruses (especially from Flaviviridae, Picornaviridae and Coronaviridae 
families) to remodel cellular membranes and generate PI4P lipid-enriched organelles 
specialized for viral replication.20 
A few PI4KIIIβ inhibitors with antiviral activity against a panel of picornaviruses have been 
reported recently (Figure 1).21-23 Generally, chemical inhibition of PI4KIIIβ does not 
influence cell viability.24 One possible explanation might be that while the small amounts of 
PI4P produced by other PI4K isoforms could be enough to support cell trafficking and 
signaling, it would not be sufficient to sustain viral RNA synthesis.20 A major aim in the 
development of PI4KIIIs inhibitors is to achieve selective inhibition of the α or β isoforms. 
Among known PI4KIIIs inhibitors, compound 1 (PIK93) is about 100-fold more potent 
against the PI4KIIIβ isoform, although it also has detectable activity towards PI3-kinases.25,26 
 
Figure 1. Representative PI4KIIIβ inhibitors. 
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Considering the growing need for novel broad-spectrum antivirals to fight emerging 
epidemics and the link between respiratory viruses and pulmonary exacerbation in cystic 
fibrosis patients, our aim was the development of a new class of multi-target agents active 
both as broad-spectrum antivirals (by targeting PI4KIIIβ) and as correctors of the F508del-
CFTR folding defect responsible for >90% of CF cases. We here report the discovery of the 
first small-molecule compounds able to simultaneously act as moderately efficacious 
correctors of the F508del-CFTR folding defect and broad-spectrum antivirals against a panel 
of enteroviruses (linked to CF pulmonary exacerbations). 
 
RESULTS AND DISCUSSION 
Drug repurposing and polypharmacology are two very attractive approaches in modern 
drug discovery. The first offers the possibility of recycling known drugs or advanced drug 
candidates developed for a different disease. The second results in simultaneous action on 
different targets/diseases with a single, rationally designed drug.27,28 In particular, 
polypharmacology aims at producing multi-target agents whose interference with multiple 
biochemical pathways offers an advantage - in terms of drug load, efficacy and safety - over 
combination therapy. This approach is well suited to complex diseases that generally require 
the simultaneous administration of many different drugs. Considering the increasing number 
of reports on the connection between enterovirus infections and pulmonary exacerbations in 
CF patients, we reasoned that an ideal drug candidate for such closely related diseases might 
be a multi-target agent able to act, at the same time, on proteins/pathways implicated in 
enterovirus replication (PI4KIIIβ) and on F508del-CFTR biogenesis. At the beginning of this 
work, the X-ray structures of the above targets were not available for a structure-based study. 
We therefore developed a PI4KIIIβ homology model to be used for the design of PI4KIIIβ 
inhibitors, selecting those whose chemical scaffolds resemble known CFTR 
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correctors/potentiators. The structure of the complex of PI3Kγ with compound 1 (PDB ID: 
2CHZ)26 has been used to build the homology model of PI4KIIIβ by using Prime software 
(see methods): this structure shows an identity of 30%, a positive of 52% and a score of 322. 
The presence of 1 in the structure of PI3Kγ allowed us to identify its likely binding site in 
PI4KIIIβ and hypothesize its binding mode. A 10 ns molecular dynamics simulation on the 
modeled PI4KIIIβ protein containing compound 1 was performed using the software 
Desmond.29 In the latter (equilibrated) part of the trajectory (last 2 ns) 100 frames were 
extracted and clusterized on the basis of RMSD. Five clusters were obtained. All PI4Kβ 
inhibitors available in Pubchem30 were docked in the compound 1 binding site of each cluster 
and the frame with the best correlation between docking score and enzymatic activity was 
selected for virtual screening. A high-throughput docking (HTD) approach was then applied 
to the compound 1 binding site in our PI4KIIIβ model to identify high affinity hits within the 
Asinex database collection.31 Compound selection was based on the ranking score and visual 
inspection of the PI4KIIIβ catalytic site, but also took into account the 2D similarity to 
known CFTR correctors/potentiators. Thirteen commercially available compounds (5-17, 
Figure 2), four of which (6, 11, 16, 17) resemble known CFTR correctors,32,33 were selected 
for biological investigation. These computational results were confirmed on the recently 
released crystal structure of PI4KIIIβ co-crystallized with compound 1, and this structure 
(PDB ID: 4D0L) was used for all the following simulations.34  
These commercially available compounds were then tested both against the PI4KIIIβ 
enzyme and in a virus-cell-based replication assay. In particular these compounds were 
evaluated for antiviral activity against a panel of enteroviruses that are representative of all 
major species: enterovirus group A (EV71), group B (coxsackievirus B3, CVB3, and 
echovirus 11, ECHO11), group C (poliovirus 1, PV1), group D (enterovirus 68, EV68), 
rhinovirus group A (RV02) and rhinovirus group B (RV14). Among the selected compounds, 
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only the bithiazole 17 showed activity in cell-free and cell-based assays and possesses a 
chemical scaffold (the bithiazole) of a known family of CFTR correctors (Figure 2).33,35 
Compound 17 was therefore selected as a promising starting point for further structure-based 
optimization.  
 
Figure 2. Chemical structure of compounds selected by virtual screening and activity profile 
of the hit compound 17. 
Chemistry 
Compound 17 was initially resynthesized to validate the biological activity of the 
commercial sample and to set up a synthetic protocol for its chemical diversification starting 
from cheap and commercially available building blocks (Scheme 1). 
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Scheme 1.
. Reagents and conditions: (a) EtOH, reflux, 12 h, 95%; (b) 48% aqueous HBr, Br2, 
1,4-dioxane, 60 °C, 3 h, 90%; (c) (i) benzoyl isothiocyanate, DCM, rt, 12 h, (ii) NaOH 1N, 
THF, reflux, 3 h, 72%; (d) EtOH, reflux, 1 h, 84%; (e) acetyl chloride, Et3N, DCM, rt, 15 h, 
77%. 
 
Thiourea 18 was condensed with 3-chloro-2,4-pentadione 19 in refluxing ethanol to afford 
1-(2-amino-4-methylthiazol-5-yl)ethanone 20 in nearly quantitative yield,36 followed by 
bromination α to the carbonyl to give compound 21. The subsequent condensation of 
intermediate 21 with 1-(3-acetylphenyl)thiourea 23 gave bithiazole 24 that was finally N-
acetylated to obtain the desired compound 17. Thiourea 23 was synthesized by reaction of 3’-
aminoacetophenone 22 with benzoyl isothiocyanate, followed by a basic hydrolysis to 
remove the benzoyl group.37 
Docking studies on compound 17 (see Molecular modeling and SAR section) showed a 
pattern of interactions within the ATP-binding pocket of PI4KIIIβ very similar to that of the 
reference compound 1. The proposed binding mode of 17 suggested that two main portions of 
this molecule could be functionalized to explore the biologically relevant chemical space: i) 
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the 2-amino group on the 4-methylthiazole ring (left part) and, ii) the phenyl ring (right part). 
We first explored the chemical space around the left part of compound 17, introducing 
bulkier groups and urea/thiourea functions in place of the acetamide moiety. The intermediate 
24 represents in fact an advanced intermediate that could be easily functionalized on the 2-
amino group to give a series of functionalized derivatives (25a-g and 26a-d) (Scheme 2). 
 
Scheme 2. Reagents and conditions: (a) method A (for 25a-c), R1COCl (for 25a,b) or 
(R1CO)2O (for 25c), Et3N, DCM, rt, 12-15 h, 65-80%; method B (for 25d-f) R
1COCl, Et3N, 
DCM, reflux, 15 h, 65-75%; method C (for 25g), (R1CO)2O, Et3N, DMF, 50 °C, 12 h, 63%; 
(b) R2NCX, pyridine, reflux, 12-18 h, 52-69%. 
 
Compound 24 was first reacted with different acyl chlorides or anhydrides to obtain 
compounds 25a-g, while the urea/thiourea derivatives 26a-d were synthesized by reacting 24 
with the appropriate isocyanates/isothiocyanates. We also decided to replace the acetamide 
moiety of compound 17 with chain-extended ureidic groups for the SAR development. 
Unfortunately, the synthesis of compounds 30a,b following the approach described above 
would have required very expensive isocyanates. Thus, an alternative synthetic approach was 
used for the synthesis of 30a,b (Scheme 3): starting from 1-(2-amino-4-methylthiazol-5-
yl)ethanone 20, reaction with diphenyl carbonate gave good yields of the desired phenyl 
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carbamate 27 that reacted readily with the appropriate amines to give the urea intermediates 
28a,b.38 Similar to the synthesis of compound 17, the bromination α to the carbonyl and the 
subsequent condensation of intermediates 29a,b with the 1-(3-acetylphenyl)thiourea 23, gave 
the desired compounds 30a,b. 
 
Scheme 3. Reagents and conditions: (a) diphenyl carbonate, NaH, DMF, rt, 30 min, 67%; (b) 
4-chlorobenzylamine (for 28a) or 1-adamantylamine (for 28b), THF, 50 °C, 5-6 h, 61-93%; 
(c) 48% aqueous HBr, Br2, 1,4-dioxane, 60 °C, 3 h, 88-92%; (d) EtOH, reflux, 1 h, 78-83%. 
 
We next explored the right part of compound 17, keeping the 2-acetamido group on the left 
part of the molecule unchanged and modifying the substitution pattern of the phenyl ring on 
the right part. Since the acetamide moiety on the left part of the molecule was conserved, 
intermediate 20 was conveniently acetylated before the bromination α to the carbonyl 
(Scheme 4). Final compounds 35a-d were quickly obtained in good yields by reacting 32 
with substituted thioureas 34a-d, previously synthesized from the corresponding amines 33a-
d. 
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Scheme 4. Reagents and conditions: (a) acetyl chloride, pyridine, THF/DCM, 0 °C, 3 h, 
87%; (b) Br2, 1,4-dioxane, 50 °C, 22 h, 84%; (c) (i) benzoyl isothiocyanate, DCM, rt, 12 h, 
(ii) NaOH 1N, THF, reflux, 2 h, 72-78%; (d) EtOH, reflux, 1h, 71-85%. 
 
Then we decided to modify the central bithiazole scaffold of the hit compound 17, to get 
additional SAR information. As described in Scheme 5, we first introduced an imidazole ring 
by reacting intermediate 21with the 1-(3-acetylphenyl)guanidine 36, obtained by treating 3’-
aminoacetophenone 22 with cyanamide.39 Compound 38 was thus synthesized by acylation of 
the intermediate 37 with acetyl chloride.  
A scaffold hopping approach (FAF-drugs2 server)40 was also employed to identify 
alternatives to the bithiazole scaffold: among the molecules proposed by the software, the 
asymmetrical N,N’-diarylthiourea scaffold was considered the most promising on the basis of 
its synthetic accessibility and the antiviral activity of some closely related analogues reported 
in the literature.41 Intermediate 41 was easily obtained by addition of 3’-aminoacetophenone 
22 to 3-nitrophenyl isothiocyanate 39, followed by reduction of the nitro group with iron 
powder in acidic ethanol (Scheme 6). The subsequent acylation of the amino group led to 
final compounds 42a,b.  
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Scheme 5. Reagents and conditions: (a) cyanamide, HNO3, EtOH/H2O, reflux, 24 h, 73%; (b) 
Et3N, EtOH, reflux, 12 h, 82%; (c) acetyl chloride, Et3N, DCM, rt, 8 h, 47%. 
 
 
Scheme 6. Reagents and conditions: (a) DCM, rt, 18 h, 88%; (b) Fe, HCl, EtOH, reflux, 2 h, 
75%; (c) acetyl chloride (for 42a) or trimethylacetyl chloride (for 42b), pyridine, THF, rt, 2 
h, 67-69%. 
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Moreover we noted high chemical similarity between compound 17 and compound 46, a 
known inhibitor of DC-SIGN (dendritic cell (DC)-specific intercellular adhesion molecule-3 
grabbing nonintegrin).42 The role of DC-SIGN in the binding and transmission of different 
pathogens, including enteroviruses, has been well investigated.43 So we decided to evaluate 
the antiviral effect of compound 46 in a virus-cell-based assay and its activity on PI4KIIIβ. 
As described in Scheme 7, compound 46 was synthesized following the procedure previously 
reported for compound 17. 
 
Scheme 7.
 Reagents and conditions: (a) (i) benzoyl isothiocyanate, DCM, rt, 12 h, (ii) NaOH 
1N, THF, reflux, 3 h, 80%; (b) EtOH, reflux, 30 min, 77%; (c) propionyl chloride, Et3N, 
DCM, rt, 8 h, 68%. 
Finally, we decided to prepare two compounds (related to the hit 17) known in the CFTR 
field to evaluate the potential role of the CFTR channel in viral replication: i) compound 47a, 
which is active in correcting the F508del-CFTR defect and, ii) compound 47b, which is 
inactive in correcting the F508del-CFTR defect (Figure 3). Compound 47a,b were 
synthesized following the procedure reported in literature.44  
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Figure 3. Chemical structures of compounds 47a,b. 
 
Biology 
All the synthesized compounds were initially evaluated for their inhibitory potency against 
PI4KIIIβ kinase in vitro and for their cell-based antiviral activity: EV71 was used as the 
primary target for SAR exploration since compound 17 revealed the best and most 
reproducible antiviral activity against this virus. In particular, the antiviral activity against 
EV71 was evaluated in EV71-induced CPE-reduction assay in rhabdosarcoma (RD) cells. 
Both the EC50 values and the CC50 values were measured. Uninfected, treated cells were also 
inspected under the microscope to evaluate whether the compounds altered normal cell 
morphology. The EC50 and CC50 values allowed us to calculate the selectivity index (SI), 
defined as CC50/EC50. Compound 3 was used as a positive control. Results are summarized in 
Table 1.  
A close correlation between the antiviral activity measured in the cell-based assay and the 
inhibitory potency of the PI4KIIIβ kinase was observed, with only a few exceptions. The best 
results were obtained via modifying the left part of the molecule. In particular compounds 
25a,b, bearing respectively a propanamide and a pivalamide moiety instead of the acetamide 
function of compound 17, showed a very promising antiviral activity. 
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Table 1. Activity of synthesized derivatives in PI4KIIIβ inhibition assay and in virus-cell-
based EV71 assay.  
Compd PI4K IIIβ 
IC50 
(µM)a 
EV71 
EC50 
(µM) 
EV71 
CC50 
(µM)b 
EV71 
CC50 (µM)
c 
SId SId 
17 0.48 0.92±2.75 16.5±9.04 9.73±0.87 17.9 10.6 
25a 0.27 0.38±0.10 10.1±4.82 6.37±2.46 26.6 23.6 
25b 0.32 0.27±0.05 7.94±1.24 8.83±0.89 29.4 32.7 
25c 21.89 2.0±0.95 25.8±5.06 30.1±9.93 12.9 15.0 
25d 18.85 0.51±0.14 5.75±2.12 11.8±4.56 11.3 23.1 
25e >50 >44.6 NDe ND ND ND 
25f >50 >55.7 ND ND ND ND 
25g 4.67 1.42±0.04 42.3±4.94 101.0±15.8 29.7 71.1 
26a 7.69 NAf ND ND ND ND 
26b >50 NA ND ND ND ND 
26c 1.82 2±0.04 8.87±3.85 ND 4.4 ND 
26d >50 NA ND ND ND ND 
30a 3.95 4.77±0.28 20.9±6.97 ND 4.4 ND 
30b 12.40 NA ND ND ND ND 
35a 2.48 1.93±0.81 18.6±6.01 ND 9.64 ND 
35b 2.63 NA ND ND ND ND 
35c 1.55 1.2±0.16 9.17±0.85 ND 5.9 ND 
35d 3.71 0.68±0.04 5.59±0.32 ND 8.2 ND 
38 >50 >90.2 85.7 64.2 ND ND 
42a NA NA ND ND ND ND 
42b NA NA ND ND ND ND 
46 50.00 8.58±0.77 51.6±27.1 142.0±62.8 6 ND 
47a NA NA ND ND ND ND 
47b NA NA ND ND ND ND 
3
g
 0.06 0.73 >125 - - - 
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aValues are the mean of at least three independent experiments. bCC50 values were assessed by MTS method. 
cCC50 values were determined by microscopically detectable alteration of cell morphology. 
dSelectivity index 
(SI = CC50/EC50). 
eND = not determined. fNA = not active. gReference 13 
 
Compounds 25a,b inhibited PI4KIIIβ and exhibited a significant antiviral effect at sub-
micromolar concentrations, demonstrating a better activity than compound 17. Compound 
25g, characterized by the Boc amino group, proved to be the most interesting compound of 
the entire series showing the highest selectivity index in the EV71 cell-based assay. Also 
changing the right portion of hit compound 17 gave interesting results (compounds 35a,c,d). 
The central bithiazole scaffold proved to be essential for antiviral activity, as changing it gave 
inactive compounds (compounds 38, 42a,b). Finally, the reported compounds 46, 47a,b were 
devoid of antiviral activity and PI4KIIIβ inhibition activity.  
Based on these activity data, and considering that the SI of a promising antiviral candidate 
should be at least greater than 10, compounds 17, 25a-d, 25g were selected for further 
studies. The broad-spectrum activity of the six selected compounds was evaluated against a 
panel of enteroviruses representative of all major groups: enterovirus group B 
(coxsackievirus B3 and echovirus11, ECHO11), group C (poliovirus 1), group D (enterovirus 
68), rhinovirus group A (RV02) and rhinovirus group B (RV14) (see the Experimental 
Section for details). Results are reported in Table 2. The selected compounds showed 
micromolar and sub-micromolar activity against different enteroviruses within the tested 
panel. In addition, the antiviral activity of the less toxic compound 25g was confirmed 
against a representative panel of EV71 clinical isolates. As shown in Table 3, we could 
confirm the activity of compounds 25g against the clinically relevant EV71 specimens. Only 
the (sub)genogroup B5 appeared to be less sensitive. Furthermore we evaluated the lipid 
kinase isoform selectivity of our best PI4KIIIβ inhibitors by testing them in an in vitro 
inhibition assay on the related enzyme PI4KIIIα and PI3K-α/p85α (Table 4). 
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Table 2. Evaluation of the broad-spectrum antiviral activity of the most potent derivatives 
against a representative panel of enteroviruses. 
Compd CVB3 ECHO11 PV1 EV68 RV14 RV02 
EC50
 
(µM) 
CC50
 
(µM)  
EC50 
(µM) 
CC50 
(µM) 
EC50 
(µM) 
CC50 
(µM) 
EC50 
(µM) 
CC50 
(µM) 
EC50 
(µM) 
CC50 
(µM) 
EC50 
(µM) 
CC50 
(µM) 
17 2.17  101±
33.6 
1.57±
0.23 
>268 3.09 >269 NAa NDb >268 ND NAb ND 
25a 2.16 89.1±
16.2 
0.97 12±4.
07 
<1.52 5.49±
1.42 
NA ND NA ND >259 ND 
25b ND 20.9±
3.83 
0.72±
0.05 
5.07±
1.24 
<1.41 5.07±
1.3 
1.38 3.09 4.85±
1.09 
ND 2.01±
0.05 
ND 
25c 3.87±
0.23 
58.8±
7.14 
3.51 29.3±
1.78 
2.86±
0.36 
30.3±
3.66 
ND ND 10.6±
0.7 
ND 10.6±
0.2 
ND 
25d 2.19±
0.23 
45.1±
4.44 
1.77±
0.13 
145±2
7.6 
2.23±
0.4 
145±2
7.6 
NA ND >230 ND 2.05±
0.36 
ND 
25g 2.74±
0.17 
80.1±
6.97 
2.93 124±7
.94 
13.3±
1.9 
124±7
.94 
ND ND >232 ND ND ND 
aNA = not active. bND = not determined 
 
Results showed a higher specificity of the tested bithiazole derivatives for the PI4KIIIβ 
isoform with poor inhibition of both PI4KIIIα and PI3K-α/p85α at 100 µM concentration of 
each compound. The specificity of compound 25g was also tested on a small panel of 
unrelated kinases: it shows only a low inhibitory effect on Src and CDK6. Despite the latter 
enzymes being involved in cell cycle regulation and representing common targets of 
antitumor compounds, 25g did not show any toxicity or morphology alteration at antiviral 
concentration in the tested cell lines. In addition, recent studies indicated that Src inhibitors 
have no effect on EV71 replication45 while CDK6 seems to be down-regulated in response to 
EV71  infection.46 Finally, compounds  reported in  Table 4 were  evaluated for  their  CFTR  
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Table 3. Evaluation of the antiviral activity of compound 25g against EV71 clinical isolates.  
Genogroup Strain Genbank 
EC50 (µM)
a 
Compd 25g 
B2 11316 AB575927 <1.39 
B5 TW/96016/08 
TW/70902/08 
GQ231942 
GQ231936 
21.00 
3.58 
C2 H08300 461#812 - 0.97 
C4 TW/1956/05 
TW/2429/04 
GQ231926 
GQ231927 
<1.39 
1.17 
aAll values are based on at least three independent dose-response curves. 
 
Table 4. Inhibitory effect of selected compounds against members of PIK family and 
profiling of compound 25g against a small panel of unrelated kinases. 
Compd 
PI4KIIIβ PI4KIIIα 
PI3K-
α/p85α 
Compd kinase 
% Residual activity 
at 100 µMa IC50(µM)
a % Residual activity 
at 100 µMa 
17 0.48 52 37 25g Src FL 32 
25a 0.27 72 40 GSK3β 79 
25b 0.32 71 93 Hck FL 100 
25c 21.89 73 85 FAK 82 
25d 18.85 81 54 DYRK1A 88 
25g 4.67 69 64 ABL FL 53 
35a 2.48 58 81 FLT3 59 
35c 1.55 71 51 CDK2/cA2 62 
35d 3.71 73 100 CDK9/cT1 57 
 CDK9/cK 49 
CDK6/cD1 25 
Pim1 70 
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aValues are the mean of two independent replicates 
 
corrector/potentiator activity, to identify molecules that may be endowed with dual 
antiviral/CFTR modulator activity. As shown in Figure 4A, some of the compounds (25a, 
25d, 25g) acted as CFTR correctors, increasing steady-state levels of F508del-CFTR at the 
plasma membrane after chronic (24 hour) incubation. Compound 48 (Lumacaftor), the 
leading corrector drug,47 was used as a benchmark. This increased CFTR plasma membrane 
density was measured with a recently developed assay exploiting a CFTR fusion to a pH-
sensitive protein.48 The improvement in biogenesis also lead to increased anion permeability, 
estimated from fluorescence quenching of a CFTR-fused YFP probe following extracellular I- 
addition (Figure 4B). None of the compounds acted as "potentiators" rapidly increasing anion 
permeability, when added only immediately prior to I- addition (Figure 4C). The approved 
potentiator drug 49 (Ivacaftor) was used as a comparison.49 Overall, the drug-induced 
changes in the iodide entry rate and in membrane density followed similar patterns, 
suggesting that the chemically corrected molecules of F508del-CFTR that reached the plasma 
membrane displayed an ion-channel function similar to those corrected by treatment with 48. 
However, compound 25d appears to increase CFTR membrane density more than expected 
from its effect on anion permeability (Figure 4D). Further studies will be required to 
understand the underlying mechanism. Overall, the collected biological data indicates that a 
fine chemical tuning of the bithiazole substituents is needed to generate compounds able to 
specifically inhibit the PI4KIIIβ kinase and block the replication of different enteroviruses 
while also correcting the F508del-CFTR folding defect. It is interesting to note that the most 
promising CFTR correctors (25a, 25d, 25g) are also the most active broad-spectrum 
antivirals and represent the first example of multi-target agents for tightly associated 
pulmonary diseases like enterovirus infection and cystic fibrosis. 
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Figure 4. Effects of selected compounds on CFTR biogenesis and function. All treatments 
were carried out alongside low temperature incubation, known to improve F508del-CFTR 
membrane-localization and used to increase the fluorescence signal. A) F508del-CFTR-
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pHTomato present at the plasma membrane was quantified following 24 h incubation in 10 
µM of each drug. Incubation with 48 (Lumacaftor) was assessed in parallel, as a positive 
control. B) Anion permeability quantified using a YFP-F508del-CFTR probe following 24 h 
treatment as in A). C) Compounds (10 µM) do not cause an immediate change in anion 
permeability. Potentiator compound 49 (Ivacaftor) was used as a positive control. D) For 
most compounds, there is a similar ratio describing increase in membrane density over anion 
permeability as caused by 48 (Lumacaftor). 
 
Molecular modelling and SAR 
The hit compound 17 was docked with the Glide software50 (SP) in the ATP binding site of 
the PI4KIIIβ crystal structure (PDB ID: 4D0L)34 centering the grid on compound 1. The 
predicted binding mode and interaction profile of compound 17 is very similar to that of 
compound 1 (Figure 5). The NH-acetamide moiety of 17 is hydrogen bonded to VAL598, 
which also interact with the thiazole nitrogen. The thiazole ring is involved in a Pi-Pi 
stacking with TYR583, while the phenyl ring is involved in a Pi-cation interaction with 
LYS549. The O carbonyl moiety is hydrogen bonded to LYS377. Moreover, the binding 
mode is completed by a series of hydrophobic interactions involving LEU383, ALA602, 
VAL599, VAL602, LEU663, ILE595, TYR583, ILE671, ILE673, PRO381 and LEU374. 
The first series of derivatives of the hit compound 17 encompasses different substitution on 
the left part of the molecule (right part as per Figure 5-7 representation) by replacing the 
methyl group of the acetamide moiety with different groups. Changing the methyl of the 
acetamide with an ethyl or tert-butyl group (25a,b) caused a 2-fold increase of potency, but 
the substitution with more hydrophobic and therefore more sterically bulky groups first 
reduced the potency (25d) and then led to a complete loss of activity (25e,f). The limit seems 
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to be a tert-butoxycarbonyl group (25g) which still maintains low micromolar activity 
(Figure 6). 
 
Figure 5. a) Predicted binding mode of the hit 17 (magenta sticks) superimposed to 
compound 1 (green sticks) into the binding site of PI4KIIIβ. b) 2D ligand interaction diagram 
of 17. 
 
The substitution of the acetamide methyl with a CF3 (25c) weakened the inhibition (45-fold 
decrease) not due to steric reasons, but probably because of the electron withdrawing 
properties of the CF3 group. Changing the acetamide moiety with a ureidic moiety caused a 
slight decrease in potency (26a,c and 30a,b). The ureidic portion seems to interact with a 
double hydrogen bond to VAL598 but at the same time, the hydrophobic NH substituent 
moves away from the protein resulting in a solvation penalty (Figure 6). Finally, modifying a 
ureidic group with a thioureidic moiety caused a complete loss of activity (26b,d). 
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Figure 6. a) Superimposed binding modes of compounds 17 (purple sticks), 25a (orange 
sticks), 25b (green sticks) and 25g (pink sticks) into the binding site of PI4KIIIβ. b) 
Superimposed binding modes of compounds 26a (orange sticks), 26c (green sticks) and 30a 
(pink sticks) into the binding site of PI4KIIIβ. c) 2D ligand interaction diagram of 25b. d) 2D 
ligand interaction diagram of 30a. 
 
The second series of derivatives of the hit compound 17 comprises different substitutions on 
the right part of the molecule (left part as per Figure 5-7 representation) by changing the 
substitution pattern of the phenyl ring. A change in the position of the acetyl group reduces 
the potency by about 10-fold (35d), and the same happens by introducing hydroxy and 
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methoxy groups in the meta position (35b,c). The precise positioning of the hydrogen-bond 
acceptor on the phenyl ring seems therefore important in improving the affinity for the 
enzyme. Surprisingly, the deletion of the ketonic group reduces but does not abolish activity 
(35a). The lack of the substituent on the phenyl ring deletes a hydrogen bond, but allows 
optimization of the other interactions, in particular the Pi-cation with lysine 549. 
The last series of derivatives of the hit compound 17 encompasses modifications of the 
bithiazole scaffold and closely related analogues reported as DC-SIGN inhibitors and CFTR 
correctors. Replacement of the thiazole group of compound 17 with an imidazole (38) or 
conversion of the bithiazole scaffold into a N,N’-diarylthiourea (42a,b) changes the binding 
mode and abolishes the activity. Finally, also the DC-SIGN inhibitor 46 and CFTR correctors 
47a,b presented a suboptimal interaction profile with PI4KIIIβ and resulted in a complete 
loss of activity. As reported by Warrem et al.51, docking programs and scoring functions 
present a few limitations in correlating subtle structural differences of active ligands with 
their enzymatic activity. This error is quite limited within homologous series of compounds 
but it can be very important for structurally unrelated compounds.52 Our docking studies were 
in fact able to distinguish between active and inactive compounds but it is no coincidence that 
the reference compound 3, whose scaffold is very different from those of our series, showed a 
docking score that is not in line with its enzymatic potency (Table 5). The most active 
compounds 17, 25a and 25b also showed the best specificity for PI4KIIIβ over PI4KIIIα, 
which seems to depend on the steric hindrance of the acetamide substitution. In fact, 
considering compounds 17, 25a, 25b, 25g and 25d that differ only for the bulkiness of the 
amide substituents in position C2 of the thiazole (methyl, ethyl, tert-butyl, tert-butoxy and 
phenyl, respectively), the affinity for PI4KIIIα decreases going from 17 to 25d (see Table 4).  
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Table 5. Correlation between IC50 and docking score for the synthesized compounds.  
Compd PI4K IIIβ 
IC50 
(µM)a 
Docking 
scoreb 
Compd PI4K IIIβ 
IC50 (µM)
a 
Docking 
scoreb 
35d 3.71 -8,297 25e >50 -7,431 
30b 12.40 -8,222 26d >50 -7,4 
26a 7.69 -8,172 25f >50 -7,356 
26c 1.82 -8,108 38 >50 -7,355 
17 0.48 -8,035 42a >50 -7,251 
25a 0.27 -8,012 26b >50 -7,144 
25d 18.85 -7,983 42b >50 -7,052 
30a 3.95 -7,97 25c 21.90 -6,678 
35b 2.63 -7,726 3c 0.06 -6,553 
46 50.00 -7,644 47b >50 -6,424 
25g 4.67 -7,63 47a >50 -6,148 
35c 1.55 -7,605 25e >50 -7,431 
35a 2.48 -7,6    
25b 0.32 -7,484    
aValues are the mean of at least three independent experiments. bDocking score was calculated by the software 
Gold and expressed as Kcal/mol. cReference 13 
The higher the bulkiness in C2 of the thiazole, the lower the affinity for PI4KIIIα over 
PI4KIIIβ with the phenyl substituent (25d) representing the highest tolerated hindrance after 
which the inhibition of PI4KIIIβ is also compromised. The reason for the specificity of these 
compounds towards PI4KIIIβ seems to depend on the different opening (compared to the α 
isoform) of a specific loop that in the β isoform goes from ILE595 to ILE604 (Figure 7). In 
fact in this portion of protein, the sequence of PI4KIIIβ resembles more the sequence of PI3K 
(α, γ end δ) than the sequence of PI4KIIIα. In particular, the presence of a cysteine residue in 
position 30 of PI4KIIIα (corresponding to proline 597 in PI4KIIIβ) could change the fold of 
this “selectivity loop”.  
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Figure 7. Observed binding mode of 25a (yellow sticks) superimposed to compound 1 
(magenta sticks) into the binding site of PI4KIIIβ (green ribbons). The orange ribbons 
represent the modelled structure of PI4KIIIα. 
 
CONCLUSIONS 
An increasing number of reports suggest a causal link between enterovirus infections and 
pulmonary exacerbations in CF patients. We report the discovery of a new class of multi-
target agents active as broad-spectrum antivirals and correctors of the F508del-CFTR folding 
defect. To identify these drug candidates, we first carried out a virtual screening on the 
PI4KIIIβ (a host protein involved in enterovirus replication) catalytic site to select 
commercially available compounds: our choice was based on the best-predicted affinity for 
the target kinase and 2D similarity (in a few cases) to known CFTR correctors/potentiators. 
Among the selected compounds, hit 17 showed activity in cell-free PI4KIIIβ inhibition assay 
and cell-based enterovirus replication assays and was therefore considered a promising 
starting point for further structure-based optimization. A small collection of analogues of 
compound 17 was then designed, synthesized and biologically evaluated for their i) activity 
against panel of enteroviruses representative of all major groups; ii) inhibition of lipid kinases 
PI4KIIIβ, PI4KIIIα and PI3K-α/p85α; iii) corrector/potentiator activity on F508del-CFTR. 
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Three compounds (25a, 25d, 25g) were finally identified as novel multi-target agents able to 
act as broad-spectrum-antivirals (enterovirus family) and as correctors of F508del-CFTR 
folding defect. These compounds represent a valuable starting point to develop a novel 
polypharmacological approach for the treatment of closely-related pulmonary diseases such 
as cystic fibrosis and enterovirus infections with a single pill. 
 
EXPERIMENTAL SECTION 
Molecular modeling 
Homology modeling 
The structure of PI4KIIIβ was built with the Prime53 38013 software on the basis of the 
crystal structure 2CHZ using ClustalW for sequence alignment and knowledge-based as 
building method. The structure of PI4KIIIα was built with the online server 3D-JIGSAW54 on 
the basis of the crystal structure 4D0L. 
Molecular dynamics 
The structure of modelled PI4KIIIβ was aligned to the 2CHZ structure. Compound 1 was 
extracted from 2CHZ and was manually introduced in the structure of PI4KIIIβ. A molecular 
dynamics simulation of the resulting complex was performed using Desmond v40013. The 
complex was neutralized using sodium counter ions. The complex and the counter ions were 
immersed in a orthorhombic periodic SPC water bath that extended about 10 Å in each 
direction. After an initial default relaxation protocol, a MD production run was performed for 
10 ns with a time step of 2 fs. 
Virtual screening 
From the last 2 ns of the dynamics simulation 100 frames were extracted and clustered on 
the basis of RMSD. Five clusters were generated. The protein representative of each cluster 
was processed with the Schrödinger Suite 2014-355 Protein Preparation Wizard tool. On each 
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structure a grid was generated with the software Glide 65013 centering the grid on compound 
1, then all PI4KIIIβ ligands available from the Pubchem database were docked with the SP 
protocol. Structures were selected for virtual screening on the basis of their enrichment 
factor. The Mid Asinex database was extracted from the ZINC database56 and docked in the 
binding site of compound 1 using compound 1 as the center of the grid. The software Glide 
65013 with the SP protocol was used for High throughput docking. The best 1000 
compounds in terms of the docking score were selected and submitted to one more docking 
cycle of docking with the XP protocol. On the basis of the docking score and a visual 
inspection 25 compounds were selected and 13 compounds were purchased. 
Ligand preparation 
Ligands were prepared with the LigPrep57 tool available in the Schrödinger Suite 2015-4. 
Ionization states were generated at pH 7.0 ± 2.0 with Epik. 
Ligand docking 
The X-ray coordinates of PI4KIIIβ in complex with compound 1 were extracted from the 
Protein Data Bank (PDB code 4D0L). The structure was then processed with the Schrödinger 
Suite 2015-4 Protein Preparation Wizard tool.58 The A Chain was selected, water molecules 
were removed, and an exhaustive sampling of the orientations of groups, whose hydrogen 
bonding network needs to be optimized, was performed. Finally, the protein structure was 
refined to relieve steric clashes with a restrained minimization with the OPLS3 force field59 
until a final RMSD of 0.30 Å with respect to the input protein coordinates. 
Docking studies were performed using Glide60 69017 with the SP protocol. The protein 
structure, prepared as described above, was used to build the energy grid. The enclosing box 
was centered on the cocrystallized ligand. All parameters were set to their default value. The 
docking protocol was validated by redocking the cocrystallized ligand (compound 1). 
 
Page 28 of 62
ACS Paragon Plus Environment
Journal of Medicinal Chemistry
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
 29
Chemistry 
General. All commercially available chemicals were purchased from both Sigma- Aldrich 
and Alfa Aesar and, unless otherwise noted, used without any previous purification. Solvents 
used for work-up and purification procedures were of technical grade. Dry solvents used in 
the reactions were obtained by distillation of technical grade materials over appropriate 
dehydrating agents. Reactions were monitored by thin layer chromatography on silica gel-
coated aluminium foils (silica gel on Al foils, SUPELCO Analytical, Sigma-Aldrich) at 254 
and 365 nm. Where indicated, products were purified by silica gel flash chromatography on 
columns packed with Merck Geduran Si 60 (40-63 µm). 1H and 13C NMR spectra were 
recorded on BRUKER AVANCE 300 MHz and BRUKER AVANCE 400 MHz 
spectrometers. Chemical shifts (δ scale) are reported in parts per million relative to TMS. 1H-
NMR spectra are reported in this order: multiplicity and number of protons; signals were 
characterized as: s (singlet), d (doublet), t (triplet), q (quadruplet), m (multiplet), bs (broad 
signal). ESI-mass spectra were recorded on an API 150EX apparatus and are reported in the 
form of (m/z). Elemental analyses were performed on a Perkin-Elmer PE 2004 elemental 
analyzer. Melting points were taken using a Gallenkamp melting point apparatus and were 
uncorrected. All final compounds showed chemical purity ≥95% as determined by elemental 
analysis data for C, H, and N (within 0.4% of the theoretical values). 
 
Synthesis of N-(2-((3-acetylphenyl)amino)-4'-methyl-[4,5'-bithiazol]-2'-yl)acetamide (17). 
Et3N (84 µL, 0.60 mmol) was added to a stirred suspension of intermediate 24 (100 mg, 0.30 
mmol) in dry DCM (4 mL) at 0 °C. After 15 minutes acetyl chloride (32 µL, 0.45 mmol), 
diluted in dry DCM (0.5 mL), was added dropwise. The resulting solution was warmed to 
room temperature and stirred for 15 h. Next, H2O and DCM were added and the aqueous 
phase was extracted twice with DCM. The combined organic phases were washed with brine, 
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dried over Na2SO4 and evaporated. The crude was purified by flash chromatography using 
DCM/MeOH (98/2) as eluent to afford compound 17 as a yellow solid. Yield 77%; mp 244-
246 °C. MS (ESI) [M + H]+: 373.3 m/z. 1H NMR (DMSO-d6 300 MHz): δ 2.14 (s, 3H), 2.51 
(s, 3H), 2.63 (s, 3H), 6.95 (s, 1H), 7.48 (t, 1H, J = 7.9 Hz), 7.56 (d, 1H, J = 7.9 Hz), 7.77 (d, 
1H, J = 7.9 Hz), 8.51 (s, 1H), 10.56 (s, 1H), 12.06 (s, 1H). 13C NMR (DMSO-d6 100.6 MHz): 
δ 17.56, 22.92, 27.42, 103.25, 116.75, 120.52, 121.44, 121.65, 129.79, 138.11, 141.81, 
143.21, 143.29, 155.58, 162.92, 168.73, 198.28. Anal. (C17H16N4O2S2) C, H, N. 
Synthesis of 1-(2-amino-4-methylthiazol-5-yl)ethanone (20). A solution of thiourea 18 (283 
mg, 3.72 mmol) and 3-chloro-2,4-pentanedione 19 (419 µL, 3.72 mmol) in ethanol (20 mL) 
was heated at reflux for 12 h, and then the reaction mixture was cooled down to 0 °C. The 
precipitate was separated by filtration over a Buchner funnel and washed with cold ethanol 
and ether to afford the product 20 as a white solid. Yield 95%. MS (ESI) [M + H]+: 157.2 
m/z. 1H NMR (DMSO-d6 400 MHz): δ 2.44 (s, 3H), 2.52 (s, 3H), 9.49 (bs, 2H).  
Synthesis of 1-(2-amino-4-methylthiazol-5-yl)-2-bromoethanone (21). A suspension of 
intermediate 20 (500 mg, 3.20 mmol) in 48% HBr solution in water (10 mL) was warmed to 
60 °C. A solution of Br2 (148 µL, 2.88 mmol) in 1,4-dioxane (10 mL) was added dropwise 
and the reaction mixture was heated at 60 °C for 3 h. After cooling down to room 
temperature, saturated aqueous NaHCO3 solution and ethyl acetate were added and the 
aqueous phase was extracted three times with ethyl acetate. The combined organic phases 
were washed with brine, dried over Na2SO4 and concentrated under vacuum to obtain 
compound 21, used in the next step without any further purification. Yield 90%. MS (ESI) 
[M + H]+: 235.0 m/z, [M + 2 + H]+: 237.1 m/z. 1H NMR (DMSO-d6 400 MHz): δ 2.46 (s, 
3H), 4.48 (s, 2H), 9.18 (bs, 2H).  
Synthesis of 1-(3-acetylphenyl)thiourea (23). Benzoyl isothiocyanate (547 µL, 4.07 mmol) 
was added dropwise to a solution of 3’-aminoacetophenone 22 (500 mg, 3.70 mmol) in dry 
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DCM (12 mL) and the mixture was stirred at room temperature for 12 h. The solvent of 
reaction was evaporated, the residue was dissolved in THF/NaOH 1N (1/1, 15 mL) and the 
mixture was refluxed for 3 h. After cooling to room temperature, H2O and ethyl acetate were 
added and the aqueous phase was extracted twice with ethyl acetate. The combined organic 
phases were dried over Na2SO4 and evaporated. The resulting solid was crystallized from 
ether. Yield 72%. MS (ESI) [M + H]+: 195.1 m/z. 1H NMR (DMSO-d6 400 MHz): δ 2.57 (s, 
3H), 7.46 (t, 1H, J = 7.9 Hz), 7.55 (bs, 2H), 7.70-7.73 (m, 2H), 8.03 (s, 1H), 9.89 (s, 1H).  
Synthesis of 1-(3-((2'-amino-4'-methyl-[4,5'-bithiazol]-2-yl)amino)phenyl)ethanone (24). 
Intermediates 21 (200 mg, 0.85 mmol) and 23 (165 mg, 0.85 mmol) were suspended in 
ethanol (5 mL) and the mixture was heated at reflux for 1 h. Then saturated aqueous NaHCO3 
solution and ethyl acetate were added to the mixture and the aqueous phase was extracted 
three times with ethyl acetate. The combined organic phases were washed with brine, dried 
over Na2SO4 and concentrated under vacuum. Ether was added to the crude and the solid 
obtained was filtered over a Buchner funnel, washed with ether and used in the following 
step without any further purification. Yield 84%. MS (ESI) [M + H]+: 331.3 m/z. 1H NMR 
(DMSO-d6 300 MHz): δ 2.35 (s, 3H), 2.60 (s, 3H), 6.67 (s, 1H), 7.09 (bs, 2H), 7.46 (t, 1H, J 
= 7.9 Hz), 7.55 (d, 1H, J = 7.9 Hz), 7.75 (d, 1H, J = 7.9 Hz), 8.40 (s, 1H), 10.55 (s, 1H). 
General Procedure for the Synthesis of Compounds 25a-g.  
Method A (for 25a-c). Et3N (84 µL, 0.60 mmol) was added to a stirred suspension of 
intermediate 24 (100 mg, 0.30 mmol) in dry DCM (4 mL) at 0 °C. After 15 minutes the 
proper acyl chlorides or anhydride (0.45 mmol), diluted in dry DCM (0.5 mL), were added 
dropwise. The resulting solution was warmed to room temperature and stirred for 12-15 h. 
Next, H2O and DCM were added and the aqueous phase was extracted twice with DCM. The 
combined organic phases were washed with brine, dried over Na2SO4 and evaporated. The 
crude was purified by flash chromatography using DCM/MeOH (98/2) as eluent. 
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N-(2-((3-acetylphenyl)amino)-4'-methyl-[4,5'-bithiazol]-2'-yl)propionamide (25a). Yield 
75%; mp 244-246 °C. MS (ESI) [M + H]+: 387.1 m/z. 1H NMR (DMSO-d6 400 MHz): δ 1.11 
(t, 3H, J = 7.5 Hz), 2.45 (q, 2H, J = 7.5 Hz), 2.52 (s, 3H), 2.64 (s, 3H), 6.95 (s, 1H), 7.50 (t, 
1H, J = 7.9 Hz), 7.57 (d, 1H, J = 7.9 Hz), 7.82 (d, 1H, J = 7.9 Hz), 8.47 (s, 1H), 10.56 (s, 
1H), 12.03 (s, 1H). 13C NMR (DMSO-d6 100.6 MHz): δ 9.63, 17.56, 27.43, 28.69, 103.25, 
116.72, 120.47, 121.49, 121.63, 129.82, 138.11, 141.82, 143.24, 143.33, 155.62, 162.94, 
172.36, 198.28. Anal. (C18H18N4O2S2) C, H, N. 
N-(2-((3-acetylphenyl)amino)-4'-methyl-[4,5'-bithiazol]-2'-yl)pivalamide (25b). Yield 80%; 
mp 232-234 °C. MS (ESI) [M + H]+: 415.4 m/z. 1H NMR (DMSO-d6 400 MHz): δ 1.25 (s, 
9H), 2.53 (s, 3H), 2.63 (s, 3H), 6.95 (s, 1H), 7.50 (t, 1H, J = 7.9 Hz), 7.57 (d, 1H, J = 7.9 Hz), 
7.85 (d, 1H, J = 7.9 Hz), 8.43 (s, 1H), 10.57 (s, 1H), 11.79 (s, 1H). 13C NMR (DMSO-d6 
100.6 MHz): δ 16.45, 26.90, 27.05 (3x), 39.24, 102.80, 117.29, 120.96, 122.25, 122.46, 
129.67, 138.02, 140.79, 142.33, 143.58, 156.98, 163.28, 176.67, 198.36. Anal. 
(C20H22N4O2S2) C, H, N. 
N-(2-((3-acetylphenyl)amino)-4'-methyl-[4,5'-bithiazol]-2'-yl)-2,2,2-trifluoroacetamide 
(25c). Yield 65%; mp 254-256 °C. MS (ESI) [M + H]+: 427.1 m/z. 1H NMR (DMSO-d6 400 
MHz): δ 2.54 (s, 3H), 2.63 (s, 3H), 7.14 (s, 1H), 7.50 (t, 1H, J = 7.9 Hz), 7.58 (d, 1H, J = 7.9 
Hz), 7.75 (d, 1H, J = 7.9 Hz), 8.47 (s, 1H), 10.64 (s, 1H), 14.05 (s, 1H). 13C NMR (DMSO-d6 
100.6 MHz): δ 15.84, 27.41, 105.27, 115.80, 116.68, 120.50, 121.44, 121.79, 129.86, 138.12, 
141.59, 143.31, 143.48, 155.43, 163.45, 168.73, 198.21. Anal. (C17H13F3N4O2S2) C, H, N. 
Method B (for 25d-f). Et3N (84 µL, 0.60 mmol) was added to a stirred suspension of 
intermediate 24 (100 mg, 0.30 mmol) in dry DCM (4 mL) at 0 °C. After 15 minutes the 
proper acyl chlorides (0.45 mmol), diluted in dry DCM (0.5 mL), were added dropwise. The 
resulting solution was warmed to room temperature and heated at reflux for 15 h. Next, H2O 
and DCM were added and the aqueous phase was extracted twice with DCM. The combined 
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organic phases were washed with brine, dried over Na2SO4 and evaporated. The crude was 
purified by flash chromatography using DCM/MeOH (99/1) as eluent. 
N-(2-((3-acetylphenyl)amino)-4'-methyl-[4,5'-bithiazol]-2'-yl)benzamide (25d). Yield 75%; 
mp 199-200 °C. MS (ESI) [M + H]+: 435.3 m/z. 1H NMR (DMSO-d6 400 MHz): δ 2.58 (s, 
3H), 2.66 (s, 3H), 7.02 (s, 1H), 7.49-7.66 (m, 5H), 7.83 (d, 1H, J = 7.9 Hz), 8.12 (d, 2H, J = 
7.8 Hz), 8.50 (s, 1H), 10.59 (s, 1H), 12.62 (s, 1H). 13C NMR (DMSO-d6 100.6 MHz): δ 
17.42, 27.44, 103.60, 116.76, 121.52, 121.66, 128.61, 129.02, 129.06 (2x), 129.83 (2x), 
132.59, 133.31, 138.12, 141.82, 143.23, 143.29, 155.72, 163.02, 167.79, 198.30. Anal. 
(C22H18N4O2S2) C, H, N. 
N-(2-((3-acetylphenyl)amino)-4'-methyl-[4,5'-bithiazol]-2'-yl)-4-iodobenzamide (25e). 
Yield 65%; mp 220-223 °C. MS (ESI) [M + H]+: 561.3 m/z. 1H NMR (DMSO-d6 400 MHz): 
δ 2.58 (s, 3H), 2.66 (s, 3H), 7.01 (s, 1H), 7.50 (t, 1H, J = 7.9 Hz), 7.58 (d, 1H, J = 7.9 Hz), 
7.81 (d, 1H, J = 7.9 Hz), 7.88 (d, 2H, J = 8.5 Hz), 7.94 (d, 2H, J = 8.5 Hz), 8.50 (s, 1H), 
10.58 (s, 1H), 12.70 (s, 1H). 13C NMR (DMSO-d6 100.6 MHz): δ 17.33, 27.45, 101.14, 
103.65, 116.77, 121.03, 121.51, 121.67, 129.82, 130.44 (2x), 132.34, 137.95 (2x), 138.12, 
141.81, 143.16, 143.29, 154.99, 163.02, 165.15, 198.30. Anal. (C22H17IN4O2S2) C, H, N. 
N-(2-((3-acetylphenyl)amino)-4'-methyl-[4,5'-bithiazol]-2'-yl)-4-methylbenzamide (25f). 
Yield 72%; mp 243-244 °C. MS (ESI) [M + H]+: 449.2 m/z. 1H NMR (DMSO-d6 400 MHz): 
δ 2.40 (s, 3H), 2.58 (s, 3H), 2.66 (s, 3H), 7.01 (s, 1H), 7.36 (d, 2H, J = 8.0 Hz), 7.50 (t, 1H, J 
= 7.9 Hz), 7.57 (d, 1H, J = 7.9 Hz), 7.82 (d, 1H, J = 7.9 Hz), 8.02 (d, 2H, J = 8.0 Hz), 8.50 (s, 
1H), 10.58 (s, 1H), 12.55 (s, 1H). 13C NMR (DMSO-d6 100.6 MHz): δ 17.76, 21.55, 27.44, 
103.55, 116.75, 120.52, 121.51, 121.66, 128.63 (2x), 129.62 (2x), 129.83, 131.51, 138.13, 
141.42, 141.83, 143.26, 143.39, 155.78, 163.00, 168.09, 198.31. Anal. (C23H20N4O2S2) C, H, 
N. 
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Method C (for 25g). Et3N (84 µL, 0.60 mmol) was added to a stirred suspension of 
intermediate 24 (100 mg, 0.30 mmol) in dry DMF (4 mL) at 0 °C. After 15 minutes Boc 
anhydride (0.60 mmol), diluted in dry DMF (0.5 mL), was added dropwise under vigorous 
stirring. The resulting solution was warmed to room temperature and heated at 50 °C for 12 
h. Next, H2O and ethyl acetate were added and the aqueous phase was extracted twice with 
ethyl acetate. The combined organic phases were washed with brine, dried over Na2SO4 and 
evaporated. The crude was purified by flash chromatography using DCM/MeOH (98/2) as 
eluent. 
Tert-butyl (2-((3-acetylphenyl)amino)-4'-methyl-[4,5'-bithiazol]-2'-yl)carbamate (25g). 
Yield 63%; mp 235-236 °C. MS (ESI) [M + H]+: 431.5 m/z. 1H NMR (DMSO-d6 400 MHz): 
δ 1.50 (s, 9H), 2.47 (s, 3H), 2.63 (s, 3H), 6.92 (s, 1H), 7.49 (t, 1H, J = 7.9 Hz), 7.56 (d, 1H, J 
= 7.9 Hz), 7.80 (d, 1H, J = 7.9 Hz), 8.50 (s, 1H), 10.54 (s, 1H), 11.39 (s, 1H). 13C NMR 
(DMSO-d6 100.6 MHz): δ 17.51, 27.42, 28.37 (3x), 79.61, 103.15, 116.70, 120.03, 121.24, 
121.65, 128.34, 138.55, 141.83, 143.41, 143.62, 155.67, 157.03, 168.39, 198.32. Anal. 
(C20H22N4O3S2) C, H, N. 
General Procedure for the Synthesis of Compounds 26a-d. A solution of intermediate 24 
(100 mg, 0.30 mmol) and the proper isocyanate or isothiocyanate (0.45 mmol) in pyridine (2 
mL) was heated at reflux for 12-18 h. The mixture was cooled to room temperature and 
diluted with ethyl acetate. The organic phase was washed with saturated aqueous NH4Cl 
solution and brine, dried over Na2SO4, and concentrated under vacuum. The crude was 
purified by flash chromatography using DCM/MeOH (98/2) as eluent.  
1-(2-((3-acetylphenyl)amino)-4'-methyl-[4,5'-bithiazol]-2'-yl)-3-phenylurea (26a). Yield 
59%; mp 236-239 °C. MS (ESI) [M + H]+: 450.3 m/z. 1H NMR (DMSO-d6 400 MHz): δ 2.51 
(s, 3H), 2.64 (s, 3H), 6.92 (s, 1H), 7.05 (t, 1H, J = 7.4 Hz), 7.33 (t, 2H, J = 7.4 Hz), 7.48-7.52 
(m, 3H), 7.57 (d, 1H, J = 7.8 Hz), 7.80 (d, 1H, J = 7.8 Hz), 8.47 (s, 1H), 8.99 (s, 1H), 10.52 
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(s, 1H), 10.55 (s, 1H). 13C NMR (DMSO-d6 100.6 MHz): δ 17.29, 27.43, 102.86, 116.73, 
119.02 (2x), 121.46, 121.62, 123.17, 128.20, 129.39 (2x), 129.83, 138.10, 139.17, 139.43, 
141.83, 143.36, 151.90, 155.68, 162.92, 198.35. Anal. (C22H19N5O2S2) C, H, N. 
1-(2-((3-acetylphenyl)amino)-4'-methyl-[4,5'-bithiazol]-2'-yl)-3-phenylthiourea (26b). 
Yield 65%; mp 217-218 °C. MS (ESI) [M + H]+: 466.4 m/z. 1H NMR (DMSO-d6 400 MHz): 
δ 2.54 (s, 3H), 2.64 (s, 3H), 6.99 (s, 1H), 7.07 (t, 1H, J = 7.4 Hz), 7.32 (t, 2H, J = 7.4 Hz), 
7.48 (t, 1H, J = 7.8 Hz), 7.57 (d, 1H, J = 7.8 Hz), 7.69 (d, 1H, J = 7.8 Hz), 7.73 (d, 2H, J = 
7.4 Hz), 8.57 (s, 1H), 10.20 (s, 1H), 10.59 (s, 1H), 12.68 (s, 1H). 13C NMR (DMSO-d6 100.6 
MHz): δ 17.30, 27.60, 103.92, 116.74, 121.50, 121.77, 122.48, 127.80, 128.20 (2x), 128.84 
(2x), 129.81, 138.12, 138.30, 139.89, 141.73, 142.96, 155.60, 163.20, 176.12, 198.28. Anal. 
(C22H19N5OS3) C, H, N. 
1-(2-((3-acetylphenyl)amino)-4'-methyl-[4,5'-bithiazol]-2'-yl)-3-cyclohexylurea (26c). 
Yield 69%; mp 197-198 °C. MS (ESI) [M + H]+: 456.4 m/z. 1H NMR (DMSO-d6 400 MHz): 
δ 1.14-1.38 (m, 6H), 1.52-1.56 (m, 1H), 1.64-1.68 (m, 2H), 1.80-1.83 (m, 2H), 2.45 (s, 3H), 
2.61 (s, 3H), 6.53 (d, 1H, J = 7.8 Hz), 6.84 (s, 1H), 7.48 (t, 1H, J = 7.8 Hz), 7.56 (d, 1H, J = 
7.8 Hz), 7.85 (d, 1H, J = 7.8 Hz), 8.41 (s, 1H), 10.09 (s, 1H), 10.52 (s, 1H). 13C NMR 
(DMSO-d6 100.6 MHz): δ 17.53, 24.67, 25.58, 27.41 (2x), 33.12 (2x), 48.44, 102.47, 116.67, 
120.57, 121.45, 121.57, 129.81, 138.07, 141.85, 143.61, 147.01, 155.38, 157.13, 162.82, 
198.29. Anal. (C22H25N5O2S2) C, H, N. 
1-(2-((3-acetylphenyl)amino)-4'-methyl-[4,5'-bithiazol]-2'-yl)-3-cyclohexylthiourea (26d). 
Yield 52%; mp 234-236 °C. MS (ESI) [M + H]+: 472.3 m/z. 1H NMR (DMSO-d6 400 MHz): 
δ 1.24-1.37 (m, 6H), 1.52-1.56 (m, 1H), 1.63-1.67 (m, 2H), 1.85-1.93 (m, 2H), 2.49 (s, 3H), 
2.63 (s, 3H), 6.96 (s, 1H), 7.47 (t, 1H, J = 7.8 Hz), 7.56 (d, 1H, J = 7.8 Hz), 7.85 (d, 1H, J = 
7.8 Hz), 8.41 (s, 1H), 9.55 (s, 1H), 10.57 (s, 1H), 11.41 (s, 1H). 13C NMR (DMSO-d6 100.6 
MHz): δ 17.84, 24.38, 25.56, 27.50 (2x), 31.80 (2x), 52.62, 103.47, 116.67, 121.45, 121.58, 
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121.74, 129.79, 137.20, 138.11, 141.65, 142.93, 146.01, 163.00, 171.90, 198.11. Anal. 
(C22H25N5OS3) C, H, N. 
Synthesis of phenyl (5-acetyl-4-methylthiazol-2-yl)carbamate (27). 1-(2-amino-4-
methylthiazol-5-yl)ethanone 20 (1000 mg, 6.40 mmol) was added to a suspension of NaH 
60% dispersion in mineral oil (768 mg, 19.20 mmol) in DMF (15 mL) at 0 °C. Diphenyl 
carbonate (3428 mg, 16.0 mmol) was added while cooling and the reaction mixture was 
stirred for additional 30 minutes at room temperature. H2O and ethyl acetate were added and 
the aqueous phase was extracted three times with ethyl acetate. The combined organic phases 
were washed twice with an aqueous solution of LiCl (5% w/w) and brine, dried over Na2SO4 
and concentrated under vacuum. Ether was added to the crude and the white solid obtained 
was filtered over a Buchner funnel, washed with ether and used in the following step without 
any further purification. Yield: 67%. MS (ESI) [M + H]+: 277.2 m/z. 1H NMR (DMSO-d6 400 
MHz): δ 2.52 (s, 3H), 2.57 (s, 3H), 7.27-7.34 (m, 3H), 7.44-7.48 (m, 2H), 12.71 (s, 1H).  
General Procedure for the Synthesis of Compounds 28a,b. The proper amine (1.09 mmol) 
was added to a solution of intermediate 27 (300 mg, 1.09 mmol) in dry THF (15 mL). The 
mixture was heated at 50 °C for 5-6 h, after which H2O and ethyl acetate were added and the 
reaction mixture was cooled down to room temperature. The aqueous phase was extracted 
twice with ethyl acetate, the combined organic phases were washed with brine, dried over 
Na2SO4 and concentrated under vacuum. The crude was purified by flash chromatography 
using DCM/MeOH (97/3) as eluent.  
1-(5-acetyl-4-methylthiazol-2-yl)-3-(4-chlorobenzyl)urea (28a). Yield: 61%. MS (ESI) [M 
+ H]+: 324.2 m/z. 1H NMR (DMSO-d6 300 MHz): δ 2.49 (s, 3H), 2.62 (s, 3H), 4.34 (d, 2H, J 
= 5.7 Hz), 7.18 (bs, 1H), 7.33 (d, 2H, J = 8.2 Hz), 7.40 (d, 2H, J = 8.2 Hz), 11.02 (s, 1H).  
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1-(5-acetyl-4-methylthiazol-2-yl)-3-(adamantan-1-yl)urea (28b). Yield: 93%. MS (ESI) [M 
+ H]+: 334.5 m/z. 1H NMR (DMSO-d6 300 MHz): δ 1.64-1.65 (m, 6H), 1.93-1.95 (m, 6H), 
2.05-2.06 (m, 3H), 2.49 (s, 3H), 2.63 (s, 3H), 6.42 (s, 1H), 10.21 (s, 1H).  
General Procedure for the Synthesis of Compounds 29a,b. A suspension of the proper 
intermediate 28a,b (0.62 mmol) in 48% HBr solution in water (2 mL) was warmed to 60 °C. 
A solution of Br2 (42 µL, 0.81 mmol) in 1,4-dioxane (2 mL) was added dropwise and the 
reaction mixture was heated at 60 °C for 3 h. After cooling down to room temperature, 
saturated aqueous NaHCO3 solution and ethyl acetate were added and the aqueous phase was 
extracted three times with ethyl acetate. The combined organic phases were washed with 
brine, dried over Na2SO4 and concentrated under vacuum. Intermediates 29a,b were used in 
the next step without any further purification.  
1-(5-(2-bromoacetyl)-4-methylthiazol-2-yl)-3-(4-chlorobenzyl)urea (29a). Yield: 88%. MS 
(ESI) [M + H]+: 402.4 m/z, [M + 2 + H]+: 404.3 m/z, [M + 4 + H]+: 406.3 m/z. 1H NMR 
(DMSO-d6 300 MHz): δ 2.49 (s, 3H), 4.34 (d, 2H, J = 5.7 Hz), 4.46 (bs, 2H), 7.18 (bs, 1H), 
7.36 (d, 2H, J = 8.2 Hz), 7.43 (d, 2H, J = 8.2 Hz), 11.23 (s, 1H). 
1-(adamantan-1-yl)-3-(5-(2-bromoacetyl)-4-methylthiazol-2-yl)urea (29b). Yield: 92%.  
MS (ESI) [M + H]+: 412.3 m/z, [M + 2 + H]+: 414.3 m/z. 1H NMR (DMSO-d6 300 MHz): δ 
1.65-1.67 (m, 6H), 1.93-1.95 (m, 6H), 2.06-2.08 (m, 3H), 2.49 (s, 3H), 4.49 (bs, 2H), 6.43 (s, 
1H), 10.31 (s, 1H).  
General Procedure for the Synthesis of Compounds 30a,b. A suspension of intermediate 23 
(100 mg, 0.51 mmol) and the proper compound 29a,b (0.51 mmol) in ethanol (6 mL) was 
heated at reflux for 1 h. After cooling down to room temperature, saturated aqueous NaHCO3 
solution, H2O and ethyl acetate were added and the aqueous phase was extracted three times 
with ethyl acetate. The combined organic phases were washed with brine, dried over Na2SO4 
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and concentrated under vacuum. The crude was purified by flash chromatography using 
DCM/MeOH (97/3) as eluent.  
1-(2-((3-acetylphenyl)amino)-4'-methyl-[4,5'-bithiazol]-2'-yl)-3-(4-chlorobenzyl)urea 
(30a). Yield 78%; mp 240-241 °C. MS (ESI) [M + H]+: 498.2 m/z. 1H NMR (DMSO-d6 400 
MHz): δ 2.47 (s, 3H), 2.61 (s, 3H), 4.34 (d, 2H, J = 5.7 Hz), 6.86 (s, 1H), 7.09 (bs, 1H), 7.33 
(d, 2H, J = 8.2 Hz), 7.40 (d, 2H, J = 8.2 Hz), 7.48 (t, 1H, J = 7.8 Hz), 7.55 (d, 1H, J = 7.8 
Hz), 7.83 (d, 1H, J = 7.8 Hz), 8.42 (s, 1H), 10.51 (s, 1H), 10.53 (s, 1H). 13C NMR (DMSO-d6 
100.6 MHz): δ 17.50, 27.41, 42.73, 102.57, 116.67, 120.01, 121.45, 121.58, 128.78 (2x), 
129.54 (2x), 129.82, 131.89, 138.08, 139.25, 141.84, 143.21, 143.55, 154.41, 157.67, 162.84, 
198.30. Anal. (C23H20ClN5O2S2) C, H, N. 
1-(2-((3-acetylphenyl)amino)-4'-methyl-[4,5'-bithiazol]-2'-yl)-3-(adamantan-1-yl)urea 
(30b). Yield 83%; mp 227-230 °C. MS (ESI) [M + H]+: 508.5 m/z. 1H NMR (DMSO-d6 400 
MHz): δ 1.65-1.67 (m, 6H), 1.93-1.95 (m, 6H), 2.05-2.06 (m, 3H), 2.49 (s, 3H), 2.63 (s, 3H), 
6.78 (s, 1H), 6.97 (s, 1H), 7.49 (t, 1H, J = 7.8 Hz), 7.56 (d, 1H, J = 7.8 Hz), 7.81 (d, 1H, J = 
7.8 Hz), 8.46 (s, 1H), 10.21 (bs, 1H), 10.59 (s, 1H). 13C NMR (DMSO-d6 100.6 MHz): δ 
16.39, 27.47, 29.29 (3x), 36.32 (3x), 41.73 (3x), 51.16, 103.55, 116.76, 119.09, 121.49, 
121.63, 129.83, 138.08, 139.61, 141.76, 142.58, 152.13, 158.27, 163.05, 198.32. Anal. 
(C26H29N5O2S2) C, H, N. 
Synthesis of N-(5-acetyl-4-methylthiazol-2-yl)acetamide (31). Intermediate 20 (1000 mg, 
6.40 mmol) was suspended in THF/DCM (3/2, 12 mL) and the mixture was cooled down to 0 
°C. Pyridine (1.3 mL) was added, followed by the dropwise addition of acetyl chloride (683 
µL, 9.60 mmol). The reaction mixture was stirred at 0 °C for 3 h. Next, H2O and ethyl acetate 
were added and the aqueous phase was extracted three times with ethyl acetate. The 
combined organic phases were washed three times with saturated aqueous NH4Cl solution 
and brine, dried over Na2SO4 and concentrated under vacuum. Intermediate 31 was used in 
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the next step without any further purification. Yield: 87%. MS (ESI) [M + H]+: 199.3 m/z. 1H 
NMR (DMSO-d6 400 MHz): δ 2.17 (s, 3H), 2.46 (s, 3H), 2.56 (s, 3H), 12.44 (s, 1H).  
Synthesis of N-(5-(2-bromoacetyl)-4-methylthiazol-2-yl)acetamide (32). A solution of Br2 
(388 µL, 7.6 mmol) in 1,4-dioxane (8.6 mL) was added dropwise to a stirred solution of 
intermediate 31 (1200 mg, 6.05 mmol) in 1,4-dioxane (23 mL). The mixture was heated at 50 
°C for 22 h. After cooling down to room temperature, saturated aqueous NaHCO3 solution 
and ethyl acetate were added and the aqueous phase was extracted three times with ethyl 
acetate. The combined organic phases were washed with brine, dried over Na2SO4 and 
concentrated under vacuum. The crude was purified by flash chromatography using 
DCM/acetone (95/5) as eluent. Yield 84%. MS (ESI) [M + H]+: 277.3 m/z, [M + 2 + H]+: 
279.4 m/z. 1H NMR (DMSO-d6 400 MHz): δ 2.11 (s, 3H), 2.46 (s, 3H), 4.52 (bs, 2H), 12.44 
(s, 1H).  
General Procedure for the Synthesis of Intermediates 34a-d. Benzoyl isothiocyanate (547 
µL, 4.07 mmol) was added dropwise to a solution of the appropriate aniline 33a-d (3.70 
mmol) in dry DCM (12 mL) and the mixture was stirred at room temperature for 12 h. The 
solvent of reaction was evaporated, the solid was dissolved in THF/NaOH 1N (1/1, 15 mL) 
and the mixture was refluxed for 2 h. Next, H2O and ethyl acetate were added and the 
aqueous phase was extracted three times with ethyl acetate. The combined organic phases 
were dried over Na2SO4 and evaporated. Crystallization from ether afforded intermediates 
34a-d. 
1-phenylthiourea (34a). Yield 72%. MS (ESI) [M + H]+: 153.1 m/z. 1H NMR (DMSO-d6 
300 MHz): δ 7.09-7.14 (m, 1H), 7.30-7.42 (m, 6H), 9.67 (s, 1H).  
1-(3-hydroxyphenyl)thiourea (34b). Yield 74%. MS (ESI) [M + H]+: 169.2 m/z. 1H NMR 
(DMSO-d6 300 MHz): δ 6.50-6.54 (m, 1H), 6.74-6.77 (m, 1H), 6.87-6.88 (m, 1H), 7.09 (t, 
1H, J = 8.0 Hz), 7.32-7.36 (bs, 2H), 9.45 (s, 1H), 9.58 (s, 1H).  
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1-(3-methoxyphenyl)thiourea (34c). Yield 75%. MS (ESI) [M + H]+: 183.3 m/z. 1H NMR 
(DMSO-d6 300 MHz): δ 3.74 (s, 3H), 6.67-6.70 (m, 1H), 6.90-6.94 (m, 1H), 7.11-7.13 (m, 
1H), 7.22 (t, 1H, J = 8.1 Hz), 7.46-7.49 (bs, 2H), 9.73 (s, 1H).  
1-(4-acetylphenyl)thiourea (34d). Yield 78%. MS (ESI) [M + H]+: 195.4 m/z. 1H NMR 
(DMSO-d6 300 MHz): δ 2.49 (s, 3H), 7.79-7.83 (m, 2H), 7.87-8.03 (m, 4H), 10.69 (s, 1H).  
General Procedure for the Synthesis of Compounds 35a-d. A solution of intermediate 32 
(50 mg, 0.18 mmol) and the proper thiourea 34a-d (0.18 mmol) in ethanol (2.5 mL) was 
heated at reflux for 1 h. After cooling down to room temperature, saturated aqueous NaHCO3 
solution, H2O and ethyl acetate were added and the aqueous phase was extracted three times 
with ethyl acetate. The combined organic phases were washed with brine, dried over Na2SO4 
and concentrated under vacuum. The crude was purified by flash chromatography using 
DCM/MeOH (97/3) as eluent.  
N-(4'-methyl-2-(phenylamino)-[4,5'-bithiazol]-2'-yl)acetamide (35a). Yield 85%; mp 187-
189 °C. MS (ESI) [M + H]+: 331.1 m/z. 1H NMR (CDCl3 400 MHz): δ 2.19 (s, 3H), 2.57 (s, 
3H), 6.58 (s, 1H), 7.10-7.12 (m, 1H), 7.36-7.42 (m, 4H), 8.18 (s, 1H), 11.94 (s, 1H). 13C 
NMR (CDCl3 100.6 MHz): δ 17.00, 23.07, 102.63, 118.50 (2x), 121.29, 123.32, 129.54 (2x), 
140.15, 142.70, 143.31, 156.66, 164.76, 167.92. Anal. (C15H14N4OS2) C, H, N. 
N-(2-((3-hydroxyphenyl)amino)-4'-methyl-[4,5'-bithiazol]-2'-yl)acetamide (35b). Yield 
71%; mp 148-149 °C. MS (ESI) [M + H]+: 347.2 m/z. 1H NMR (acetone- d6 400 MHz): δ 
2.26 (s, 3H), 2.51 (s, 3H), 6.52-6.54 (m, 1H), 6.78 (s, 1H), 7.15-7.18 (m, 2H), 7.27 (s, 1H), 
8.45 (s, 1H), 9.30 (s, 1H), 10.85 (s, 1H). 13C NMR (acetone- d6 100.6 MHz): δ 16.51, 21.90, 
101.85, 104.58, 108.75, 109.12, 120.91, 129.81, 142.39, 143.14, 143.95, 155.28, 158.21, 
163.25, 167.72. Anal. (C15H14N4O2S2) C, H, N. 
N-(2-((3-methoxyphenyl)amino)-4'-methyl-[4,5'-bithiazol]-2'-yl)acetamide (35c). Yield 
74%; mp 118-119 °C. MS (ESI) [M + H]+: 361.2 m/z. 1H NMR (DMSO-d6 400 MHz): δ 2.14 
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(s, 3H), 2.48 (s, 3H), 3.82 (s, 3H), 6.53 (d, 1H, J = 8.2 Hz), 6.90 (s, 1H), 6.98 (s, 1H, J = 8.2 
Hz), 7.20 (t, 1H, J = 8.2 Hz), 7.71 (s, 1H), 10.42 (s, 1H), 12.06 (s, 1H). 13C NMR (DMSO-d6 
100.6 MHz): δ 17.53, 22.93, 55.52, 102.71, 105.60, 107.78, 109.65, 120.81, 130.02, 142.77, 
142.90, 143.12, 155.59, 160.40, 162.96, 168.75. Anal. (C16H16N4O2S2) C, H, N. 
N-(2-((4-acetylphenyl)amino)-4'-methyl-[4,5'-bithiazol]-2'-yl)acetamide (35d). Yield 79%; 
mp 233-235 °C. MS (ESI) [M + H]+: 373.2 m/z. 1H NMR (DMSO-d6 400 MHz): δ 2.15 (s, 
3H), 2.51 (s, 3H), 2.54 (s, 3H), 7.07 (s, 1H), 7.77 (d, 2H, J = 8.7 Hz), 7.97 (d, 2H, J = 8.7 
Hz), 10.79 (s, 1H), 12.11 (s, 1H). 13C NMR (DMSO-d6 100.6 MHz): δ 17.49, 22.93, 26.82, 
104.38, 116.33 (2x), 120.33, 130.34, 130.42 (2x), 143.41, 145.48, 152.60, 155.63, 162.37, 
168.83, 196.63. Anal. (C17H16N4O2S2) C, H, N. 
Synthesis of 1-(3-acetylphenyl)guanidine (36). Nitric acid (164 µL, 3.70 mmol) was added 
to a solution of 3’-aminoacetophenone 22 (500 mg, 3.70 mmol) in ethanol (10 mL), followed 
by addition of a solution of cyanamide (778 mg, 18.5 mmol) in a minimal amount of water. 
The mixture was heated at reflux for 24 h and concentrated in vacuum. After cooling to 0 °C, 
ether was added and the precipitate was separated by filtration over a Buchner funnel. Then 
saturated aqueous NaHCO3 solution and ethyl acetate were added to the solid and the 
aqueous phase was extracted three times with ethyl acetate. The combined organic phases 
were washed with brine, dried over Na2SO4 and concentrated under vacuum to obtain 
compound 36, used in the next step without any further purification. Yield 73%. MS (ESI) 
[M + H]+: 178.2 m/z. 1H NMR (DMSO-d6 300 MHz): δ 2.57 (s, 3H), 7.49 (bs, 3H), 7.58-7.60 
(m, 2H), 7.76-7.78 (m, 1H), 7.88 (s, 1H), 9.67 (bs, 1H). 
Synthesis of 1-(3-((4-(2-amino-4-methylthiazol-5-yl)-1H-imidazol-2-
yl)amino)phenyl)ethanone (37). A solution of intermediate 36 (150 mg, 0.85 mmol) in 
ethanol (5 mL) was added dropwise to a solution of compound 21 (200 mg, 0.85 mmol) and 
Et3N (118 µL, 0.85 mmol) in ethanol (10 mL). The mixture was heated at reflux for 12 h, 
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after which H2O and ethyl acetate were added. The organic phase was washed with saturated 
aqueous NH4Cl solution and brine, dried over Na2SO4 and concentrated under vacuum to 
obtain compound 37, used in the next step without any further purification. Yield 82%. MS 
(ESI) [M + H]+: 314.3 m/z. 1H NMR (DMSO-d6 400 MHz): δ 2.37 (s, 3H), 2.64 (s, 3 H), 7.09 
(s, 1 H), 7.65 (t, 1H, J = 7.9 Hz), 7.79 (d, 1H, J = 7.9 Hz), 7.94 (d, 1H, J = 7.9 Hz), 8.04 (s, 
1H), 9.50 (bs, 2H), 10.56 (s, 1H), 12.01 (s, 1H).  
Synthesis of N-(5-(2-((3-acetylphenyl)amino)-1H-imidazol-4-yl)-4-methylthiazol-2-
yl)acetamide (38). Et3N (89 µL, 0.64 mmol) was added to a stirred suspension of 
intermediate 37 (100 mg, 0.32 mmol) in dry DCM (4.5 mL) at 0 °C. After 15 minutes acetyl 
chloride (34 µL, 0.48 mmol), diluted in dry DCM (0.5 mL), was added dropwise. The 
resulting solution was warmed to room temperature and stirred for 8 h. Next, H2O and DCM 
were added and the aqueous phase was extracted three times with DCM. The combined 
organic phases were washed with brine, dried over Na2SO4 and evaporated. The crude was 
purified by flash chromatography using DCM/MeOH (97/3) as eluent. Yield 47%; mp 222-
225 °C. MS (ESI) [M + H]+: 356.2 m/z. 1H NMR (DMSO-d6 400 MHz): δ 2.14 (s, 3H), 2.37 
(s, 3H), 2.65 (s, 3H), 7.11 (s, 1H), 7.66 (t, 1H, J = 7.9 Hz), 7.79 (d, 1H, J = 7.9 Hz), 7.94 (d, 
1H, J = 7.9 Hz), 8.05 (s, 1H), 10.56 (s, 1H), 11.84 (s, 1H), 12.06 (s, 1H). 13C NMR (DMSO-
d6 100.6 MHz): δ 17.56, 22.56, 27.42, 116.75, 119.9, 120.51, 121.65, 127.71, 129.79, 138.10, 
140.81, 143.21, 143.28, 154.98, 162.89, 168.63, 198.32. Anal. (C17H17N5O2S) C, H, N. 
Synthesis of 1-(3-acetylphenyl)-3-(3-nitrophenyl)thiourea (40). 3’-aminoacetophenone 22 
(300 mg, 2.22 mmol) was added to a solution of 3-nitrophenyl isothiocyanate (400 mg, 2.22 
mmol) in dry DCM (6.50 mL). The solution was stirred at room temperature for 18 h. The 
precipitate was separated by filtration over a Buchner funnel and washed with ether, 
affording compound 40 as a white solid. Yield 88%. MS (ESI) [M + H]+: 316.2 m/z. 1H NMR 
(DMSO-d6 400 MHz): δ 2.58 (s, 3H), 7.52 (t, 1H, J = 7.9 Hz), 7.63 (t, 1H, J = 8.1 Hz), 7.76-
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7.78 (m, 2H), 7.92 (d, 1H, J = 7.9 Hz), 7.98 (d, 1H, J = 8.1 Hz), 8.07 (s, 1H), 8.56 (s, 1H), 
10.31 (bs, 1H), 10.33 (bs, 1H). 
Synthesis of 1-(3-acetylphenyl)-3-(3-aminophenyl)thiourea (41). Iron powder (1490 mg, 
26.67 mmol), water (7 mL) and concentrated HCl (4 drops) were added to a solution of 
compound 40 (400 mg, 1.27 mmol) in ethanol (35 mL). After heating at reflux for 2 h, the 
mixture was filtrated hot, washed with ethanol and concentrated in vacuum. The crude was 
purified by flash chromatography using DCM/MeOH (98/2) as eluent. Yield 75%. MS (ESI) 
[M + H]+: 286.1 m/z. 1H NMR (CDCl3 400 MHz): δ 2.58 (s, 3H), 3.20-3.51 (bs, 2H), 6.59-
6.62 (m, 2H), 6.68 (d, 1H, J = 7.7 Hz), 7.18 (t, 1H, J = 7.8 Hz), 7.45 (t, 1H, J = 7.8 Hz), 
7.74-7.79 (m, 2H), 7.95 (s, 1H), 8.05 (s, 1H), 8.38 (s, 1H).  
General Procedure for the Synthesis of Compounds 42a,b. The proper acyl chloride (0.53 
mmol) was added to a stirred solution of intermediate 41 (100 mg, 0.35 mmol) and pyridine 
(56 µL, 0.70 mmol) in dry THF (4 mL). The resulting solution was stirred at room 
temperature for 2 h, after which H2O and ethyl acetate were added and the aqueous phase was 
extracted three times with ethyl acetate. The combined organic phases were washed with 
brine, dried over Na2SO4 and concentrated under vacuum. The crude was purified by flash 
chromatography using DCM/MeOH (99/1) as eluent.  
N-(3-(3-(3-acetylphenyl)thioureido)phenyl)acetamide (42a). Yield 67%; mp 171-173 °C. 
MS (ESI) [M + H]+: 328.1 m/z. 1H NMR (DMSO-d6 400 MHz): δ 2.04 (s, 3H), 2.57 (s, 3H), 
7.16-7.19 (m, 1H), 7.25 (t, 1H, J = 7.9 Hz), 7.35-7.37 (m, 1H), 7.47 (t, 1H, J = 7.9 Hz), 7.71-
7.79 (m, 3H), 8.07 (bs, 1H), 9.89 (s, 1H), 9.96 (s, 1H), 9.98 (s, 1H). 13C NMR (DMSO-d6 
100.6 MHz): 23.43, 27.23, 116.20, 117.10, 119.38, 123.64, 124.55, 128.90, 128.98, 129.04, 
136.97, 139.64, 140.17, 140.52, 168.56, 180.27, 197.97. Anal. (C17H17N3O2S) C, H, N. 
N-(3-(3-(3-acetylphenyl)thioureido)phenyl)pivalamide (42b). Yield 69%; mp 157-159 °C. 
MS (ESI) [M + H]+: 370.3 m/z. 1H NMR (DMSO-d6 300 MHz): δ 1.22 (s, 9H), 2.57 (s, 3H), 
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7.14 (d, 1H, J = 7.9 Hz), 7.25 (t, 1H, J = 7.9 Hz), 7.42-7.50 (m, 2H), 7.71-7.80 (m, 3H), 8.06 
(bs, 1H), 9.25 (s, 1H), 9.89 (s, 1H), 9.94 (s, 1H). 13C NMR (DMSO-d6 100.6 MHz): δ 27.23, 
27.65 (3x), 30.90, 116.29, 117.14, 119.35, 123.68, 124.71, 128.88, 128.92, 129.10, 137.43, 
139.65, 140.20, 140.52, 176.96, 180.27, 197.97. Anal. (C20H23N3O2S) C, H, N. 
Synthesis of 1-(4-(dimethylamino)phenyl)thiourea (44). Benzoyl isothiocyanate (543 µL, 
4.04 mmol) was added dropwise to a solution of N,N-Dimethyl-p-phenylenediamine 43 (500 
mg, 3.67 mmol) in dry DCM (12 mL) and the mixture was stirred at room temperature for 12 
h. The solvent of reaction was evaporated, the solid was dissolved in THF/NaOH 1N (1/1, 15 
mL) and the mixture was refluxed for 3 h. Next, H2O and ethyl acetate were added and the 
aqueous phase was extracted three times with ethyl acetate. The combined organic phases 
were dried over Na2SO4 and evaporated. The resulting solid was crystallized from ether. 
Yield 80%. MS (ESI) [M + H]+: 196.4 m/z. 1H NMR (DMSO-d6 300 MHz): δ 2.88 (s, 6H), 
6.69 (d, 2H, J = 8.7 Hz), 7.08 (d, 2H, J = 8.7 Hz), 7.55 (bs, 2H), 9.58 (s, 1H).  
Synthesis of N
2
-(4-(dimethylamino)phenyl)-4'-methyl-[4,5'-bithiazole]-2,2'-diamine (45). 
Intermediates 21 (150 mg, 0.64 mmol) and 44 (125 mg, 0.64 mmol) were suspended in 
ethanol (6 mL) and the mixture was heated at reflux for 30 minutes. Then saturated aqueous 
NaHCO3 solution and ethyl acetate were added to the mixture and the aqueous phase was 
extracted three times with ethyl acetate. The combined organic phases were washed with 
brine, dried over Na2SO4 and concentrated under vacuum. Ether was added to the crude and 
the solid obtained was filtered over a Buchner funnel, washed with ether and used in the 
following step without any further purification. Yield 77%. MS (ESI) [M + H]+: 332.2 m/z. 
1H NMR (DMSO-d6 400 MHz): δ 2.47 (s, 3H), 2.86 (s, 6H), 6.72 (s, 1H), 6.76 (d, 2H, J = 8.8 
Hz), 7.43 (d, 2H, J = 8.8 Hz), 9.21 (bs, 2H), 10.58 (s, 1H). 
N-(2-((4-(dimethylamino)phenyl)amino)-4'-methyl-[4,5'-bithiazol]-2'-yl)propionamide 
(46). Et3N (84 µL, 0.60 mmol) was added to a stirred suspension of intermediate 45 (100 mg, 
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0.30 mmol) in dry DCM (4 mL) at 0 °C. After 15 minutes propionyl chloride (39 µL, 0.45 
mmol), diluted in dry DCM (0.5 mL), was added dropwise. The resulting solution was 
warmed to room temperature and stirred for 8 h. Next, H2O and DCM were added and the 
aqueous phase was extracted twice with DCM. The combined organic phases were washed 
with brine, dried over Na2SO4 and evaporated. The crude was purified by flash 
chromatography using DCM/MeOH (98/2) as eluent. Yield 68%; mp 222-224 °C. MS (ESI) 
[M + H]+: 388.3 m/z. 1H NMR (DMSO-d6 400 MHz): δ 1.10 (t, 3H, J = 7.6 Hz), 2.43 (q, 2H, 
J = 7.6 Hz), 2.47 (s, 3H), 2.86 (s, 6H), 6.73 (s, 1H), 6.76 (d, 2H, J = 8.8 Hz), 7.43 (d, 2H, J = 
8.8 Hz), 9.90 (s, 1H), 11.98 (s, 1H). 13C NMR (DMSO-d6 100.6 MHz): δ 8.78, 16.88, 30.43, 
40.46 (2x), 101.02, 113.74 (2x), 120.67 (2x), 121.44, 131.54, 143.10, 144.02, 147.72, 155.12, 
165.29, 171.76. Anal. (C18H21N5OS2) C, H, N. 
 
Biology 
Antiviral assays – materials and methods Assay preparation 
Enterovirus (EV): 
Rhabdosarcoma (RD) cells, Vero cells and Hela-Rh cells, subcultured in cell growth medium 
[MEM Rega3 (Cat. N°19993013; Invitrogen) supplemented with 10% FCS (Integro), 5 ml 
200 mM L-glutamine (25030024) and 5 mL 7.5% sodium bicarbonate (25080060)] at a ratio 
of 1:4 and grown for 7 days in 150 cm2 tissue culture flasks (Techno Plastic Products), were 
harvested and seeded in a 96-well plate at a cell density of 20 000 cells/well in assay medium 
(MEM Rega3, 2% FCS, 5 ml L-glutamine and 5 ml sodium bicarbonate) to perform 
standardized antiviral assay against EV71 and EVD68, CV and PV, RV02 and RV14, 
respectively. 
Antiviral activity and cytotoxicity determinations 
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Compounds were prepared as DMSO stock solution with a final compound concentration of 
10mM. The compound profiling setup was performed employing a Freedom EVO200 liquid 
handling platform (Tecan). The evaluation of the cytostatic/cytotoxic as well as the antiviral 
effect of each compound was performed in parallel within one run. Three 8-step 1-to-5 
dilution series were prepared (starting from 100 µM) in assay medium added to empty wells 
(picornaviruses: 96-well microtiter plates, Falcon, BD) or in the medium present on top of 
pre-seeded cells. Subsequently, 50 µL of a 4x virus dilution in assay medium (assay medium 
supplemented with 15 ml MgCl2 1M (Sigma, M1028) in case of RV) was added followed by 
50 µL of cell suspension. The assay plates were returned to the incubator for 2-3 
(picornavirus, 35°C for RV) days, a time at which maximal cytopathic effect (CPE) for 
picornaviruses is observed. 
For the evaluation of cytostatic/cytotoxic effects and for the evaluation of the antiviral effect 
in case of PV, CV, RV, the assay medium was replaced with 75 µL of a 5% MTS (Promega) 
solution in phenol red-free medium and incubated for 1.5 hours (37°C, 5% CO2, 95-99% 
relative humidity). Absorbance was measured at a wavelength of 498 nm (Safire2, Tecan) 
and optical densities (OD values) were converted to percentage of untreated controls. 
Analysis of the raw data, quality control of each individual dose-response curve and 
calculation, if possible, of the EC50, EC90 and CC50 values was performed employing 
ViroDM, a custom-made data processing software package. The EC50 and EC90 (values 
derived from the dose-response curve) represent the concentrations at which respectively 
50% and 90% inhibition of viral replication would be observed. The CC50 (value derived 
from the dose-response curve) represents the concentration at which the metabolic activity of 
the cells would be reduced to 50 % of the metabolic activity of untreated cells. 
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The EC50, EC90 and CC50 ± SD were, whenever possible, calculated respectively as the 
median of all the EC50, EC90 or CC50 values derived from the 3 individual dose-response 
curves. The selectivity index (SI), indicative of the therapeutic window of the compound, was 
calculated as CC50/EC50. No further statistical analysis was performed. 
 
CFTR assays 
The effects of compounds on CFTR biogenesis and function were measured using 
newly developed assays exploiting CFTR fusion probes with anion-sensitive YFP61 and pH-
sensitive pHTomato.62 Lipofectamine transfection was used for transient transfection of 
HEK293 cells. Cells plated in 96-well plates were incubated with the YFP-CFTR- or CFTR-
pHTomato- encoding plasmid48 using Lipofectamine 2000 (Life Technologies), according to 
manufacturer’s instructions. Following transfection, cell plates were returned to the 37°C 
incubator for 24 h. Plates were further incubated at 30°C for 24 h prior to imaging, with or 
without additional drug treatment.  
All imaging was carried out using ImageXpress (ImageXpress Micro XLS, Molecular 
Devices); an image-acquisition system equipped with wide-field inverted fluorescence 
microscope and fluidics robotics. Images were obtained with a 20X objective, using 
excitation/emission filters 472 ± 30 nm and 520 ± 35 nm, for YFP-CFTR and 531 ± 20 nm 
and 592 ± 20 nm for CFTR-pHTomato. In the latter assay, eGFP and Hoechst nuclear stain 
images were also acquired for each well, using excitation/emission filters 472 ± 30 nm and 
520 ± 35 nm, and 377 ± 25 nm and 447 ± 30 nm, respectively. For each plate, the laser 
intensity and exposure were optimized to achieve the highest possible fluorescence whilst 
avoiding both photobleaching and saturation (illumination intensity 100-150/225 cd, and 
exposure 0.1 – 0.2 s) 
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For the YFP-CFTR assays, before imaging, cells were washed twice with 100 µl standard 
buffer (140 mM NaCl, 4.7 mM KCl, 1.2 mM MgCl2, 5 mM HEPES, 2.5 mM CaCl2, 1 mM 
Glucose, pH 7.4). Images were taken for 150 s at a frequency of 0.5 Hz. 50 µL extracellular 
I¯ (as standard buffer with 140 mM NaCl replaced with 300 mM NaI; resulting in 100 mM 
final [I¯]) was added at 20 s, and activating compounds (50 µM Forskolin alone or together 
with 10 µM compounds for acute treatment) were added at 60 s. 
For the CFTR-pHTomato assay, before imaging, cells were washed twice with 100 µL 
standard buffer (as above). During imaging, extracellular pH was changed using addition of 
50 µL pH 6 buffer (as standard buffer, with 5 mM HEPES replaced with 10 mM MES: final 
[MES] 3.3 mM, ~ pH 6.5), and 50 µL pH 9 buffer (as standard buffer, with 5 mM HEPES 
replaced with 100 mM Tris: final [Tris] 25 mM, ~ pH 8.8). Two pHTomato images 
(acquisition frequency 0.5 Hz) were taken in each condition. To account for variation in 
transfection efficiency the pHTomato fluorescence was normalized using average 
fluorescence intensity of a soluble eGFP, co-expressed in the cytosol. Because the rise in 
pHTomato fluorescence falls largely within the 6.5 to 8.8 pH range,63 the change in 
fluorescence obtained upon increasing extracellular pH (∆Fmembrane) was used as an estimate 
of membrane-exposed CFTR. 
 
In vitro kinase inhibition assays 
Recombinant full length, HIS6-tagged PI4KIIIβ was purchased from ProQinase (Germany); 
recombinant full length, GST tagged PI4KIIIα was from Life Technologies. Recombinant 
full length, HIS6-tagged (PI3K-α) and full length, myc-tagged (p85α) PI3K-α/p85α was 
purchased from ProQinase (Germany). 
Assay conditions: 
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PI4KIIIβ, PI4KIIIα and PI3K- α/p85α reactions were performed in 10 µL using 20 mM Tris-
HCl pH 7.5, 0.125 mM EGTA, 2 mM DTT, 0.04% Triton, 3 mM MgCl2, 3 mM MnCl2, 20 
µM ATP, 0.01 µCi γ-P33 ATP, 200 µM Pi:3PS, 10% DMSO, 0.4 ng/µL of PI4KIIIβ, 16 
ng/µL of PI4KIIIα and 7.6 ng/µL of PI3K- α/p85α.  All reactions were performed at 30 °C for 
10 min. Reactions were stopped by adding 5µL of phosphoric acid 0.8%. Aliquots (10 µL) 
were then transferred into a P30 Filtermat (PerkinElmer), washed five times with 0.5 % 
phosphoric acid and four times with water for 5 min. The filter was dried and transferred to a 
sealable plastic bag, and scintillation cocktail (4 mL) was added. Spotted reactions were read 
in a scintillation counter (Trilux, Perkinelmer). IC50 values were obtained according to 
Equation (1), where v is the measured reaction velocity, V is the apparent maximal velocity 
in the absence of inhibitor, I is the inhibitor concentration, and IC50 is the 50% inhibitory 
concentration. 
v = V/{1+(I/IC50)}          (1) 
Lipidic substrate preparation: 
PI: phosphatidylinositol (Sigma); PS: 2-Oleoyl-1-palmitoyl-sn-glycero-3-phospho-L-serine 
(Sigma). PI and PS were dissolved in chloroform/methanol 9:1 and mixed at a 1:3 ratio. After 
chloroform/methanol evaporation, water was added to 1:62.5 w/v and the mixture sonicated 
to clarity. 
Kinase Panel:  
All Tyrosine- and Serine/Threonine kinase reactions were performed according to 
manufacturer’s instructions, using 10-50 ng of enzyme. Details on the nature of the substrates 
and their concentration are reported elsewhere.63 For some kinases, NP-40 or BSA was 
added. All reactions were performed in 10 µL at 30 °C for 10 min using protein low-binding 
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tubes. Reactions were stopped, transferred to filter and counted as reported in Ref. 59. 
PI4KIIIβ was purchased from Proqinase. Reactions were performed according to the 
manufacturer’s instructions and detected using ADP-Glo™ Lipid Kinase Assay (Promega). 
Supporting Information. 3D coordinates of the PI4KIIIβ and PI4KIIIα homology models. 
Molecular formula strings. This material is available free of charge via the Internet at 
http://pubs.acs.org. 
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